Completed OBSERVATIONAL NCT01727232

Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regimen in Adult's Immune Thrombocytopenia

Sponsor: Henri Mondor University Hospital

Conditions Primary Immune Thrombocytopenia

Updated 5 times since 2017 Last updated: Nov 12, 2012 Started: Jan 31, 2007 Primary completion: Jun 30, 2012 Completion: Oct 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Primary Immune Thrombocytopenia and is currently completed. Henri Mondor University Hospital leads this study, which shows 5 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Apr 2018 — Jan 2021 [monthly]

Completed

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Jan 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Henri Mondor University Hospital

Data source: Henri Mondor University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.